Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.67 |
| ▸ | QPCT | Q16769 | 1/20 | 0.67 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722521 | 0.87 | CYP11B1 (0.58) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL1024261 | 0.86 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL1775141 | 0.84 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL2729830 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL10496235 | 0.81 | TBXAS1 (0.56) | CYP11B1CYP19A1TBXAS1 | |
| Benzylimidazole SCHEMBL414 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL22063900 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL2529997 | 0.80 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL6057476 | 0.80 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL6299116 | 0.80 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP19A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | claimed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| CN-101516860-B | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG | 2012-06-27 | — | — | CN | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| CN-101516860-A | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | claimed |
| CN-1149191-C | Azetidine derivatives, Preparation and medicines containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-05-12 | — | — | CN | claimed |
| CN-1473040-A | Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity | ���ĵ�˹ҩ��ɷ�����˾ | 2004-02-04 | — | — | CN | claimed |
| CN-1393131-A | Antifungal triazole compounds | MILITARY MEDICAL UNIV NO 2 P L (CN) | 2003-01-29 | — | — | CN | claimed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | claimed |
| CN-1316991-A | Azetidine derivatives, preparation and medicines containing them | AVENTIS PHARMA SA (FR) | 2001-10-10 | — | — | CN | claimed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | claimed |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-07-18 | — | — | US | disclosed |
| US-4464382-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 703/4885CYP11B2 611/4885CYP19A1 2052/4885 |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | ALDH1A2, PDE6D, CRYAB | CYP11B1 1218/4885CYP11B2 866/4885CYP19A1 3031/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 703/4885CYP11B2 611/4885CYP19A1 2052/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 455/4885CYP11B2 427/4885CYP19A1 905/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 455/4885CYP11B2 427/4885CYP19A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.